First-line pembrolizumab in advanced urothelial carcinoma: Clinical parameters associated with efficacy in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-361 trials.
Tarih
2022Yazar
Hahn, Noah M.
Csoszi, Tibor
Powles, Thomas
Alva, Ajjai Shivaram
Castellano, Daniel E.
Ozguroglu, Mustafa
O'Donnell, Peter H.
Loriot, Yohann
Flechon, Aude
Rodriguez-Vida, Alejo
De Wit, Ronald
Cheng, Susanna Y.
Oudard, Stephane
Vulsteke, Christof
Yu, Evan Y.
Lin, Jianxin
Imai, Kentaro
Moreno, Blanca Homet
Balar, Arjun Vasant
Grivas, Petros
Üst veri
Tüm öğe kaydını gösterKoleksiyonlar
- Makale [92796]